Treatment of a Patient with Merkel Cell Skin Carcinoma Using Radiation Therapy. by Petrov, Andrej et al.
 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2018 Apr 15; 6(4):669-672.                                                                                                                                                         669 
 
ID Design Press, Skopje, Republic of Macedonia 








Treatment of a Patient with Merkel Cell Skin Carcinoma Using 














Acibadem Sistina Hospital, Skopje, Republic of Macedonia; 
2
Faculty of Medical Sciences, University Goce Delchev, Shtip, 
Republic of Macedonia 
 
Citation: Petrov A, Kraleva S, Kubelka-Sabit K, Petrova 
D. Treatment of a Patient with Merkel Cell Skin 
Carcinoma Using Radiation Therapy - A Case Report. 
Open Access Maced J Med Sci. 2018 Apr 15; 6(4):669-
672. https://doi.org/10.3889/oamjms.2018.120 
Keywords: Carcinoma; Merkel cell; Radiotherapy 
*Correspondence: Andrej Petrov. Acibadem Sistina 
Hospital, Skopje, Republic of Macedonia. E-mail: 
petrovandrej555@gmail.com 
Received: 01-Feb-2018; Revised: 30-Mar-2018; 
Accepted: 04-Apr-2018; Online first: 14-Apr-2018  
Copyright: © 2018 Andrej Petrov, Slavica Kraleva, 
Katerina Kubelka-Sabit, Deva Petrova. This is an open-
access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial 4.0 International 
License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 






BACKGROUND: Merkel cell carcinoma (MCC) is a rare, very aggressive tumour. The pathogenesis remains 
unclear, but UV radiation, immunosuppression, and the presence of Merkel cell polyomavirus in the tumour 
genome appear to have a key role. Merkel cell carcinoma is a highly aggressive tumour that often has a lethal 
end.  
CAS REPORT: A patient at 93 years of age comes for an examination by a dermatologist due to a rapidly 
growing nodular tumour growth in the forehead area. A tumour was about 3 cm in size. It had no signs of basal-
cell carcinoma, no arborising vascularisation, no pigmentations on dermoscopy. Clinically, an eventual Merkel cell 
carcinoma was considered for the patient, but other primary skin tumours had to be excluded, as well as the 
possibility that regarding the patient’s age, it may be a metastatic deposit. A skin biopsy was performed, as well 
as H-E examination and immunohistochemical analyses (positive CD56, positivity of neuroendocrine markers 
synaptophysin, chromogranin) which were in favour of Merkel cell carcinoma of the skin. After setting the 
diagnosis, our patient was treated with therapy which led to a complete withdrawal of a tumour. However, after 3 
months the patient had repeated relapse of a tumour at the same site on the forehead and metastases in the 
retroauricular lymph nodes bilaterally. It shows that the radiotherapy as monotherapy has a great effect on the 
removal of the tumour formation, but unfortunately, it has no impact on lesion recurrence. It is also compatible 
with the literature data.  
CONCLUSION: In many adult patients, as our case suggests, radiotherapy could be a good palliative treatment 







Merkel cell carcinoma (MCC) is a rare, very 
aggressive tumour, with quite common local or 
regional recurrences and with high metastatic 
potential. MCC usually develops in areas of the skin 
exposed to sunlight, in patients of advanced age. Its 
incidence has grown four times over the past decades 
due to the ageing of the population and 
immunohistochemical techniques leading to the 
diagnosis. The pathogenesis remains unclear, but UV 
radiation, immunosuppression, and the presence of 
Merkel cell polyomavirus in the tumour genome 
appear to have a key role. Toker was the author who 
first described a tumour in 1972. He used the term 
trabecular carcinoma of the skin, suggesting a 
possibility of glandular origin. Ultrastructural studies 
made 6 years later by Tang and Toker indicated a 
presence of electron-dense granules in the cytoplasm 
of the tumour cells. They suggested a neuroendocrine 
origin, similar to Merkel cells in the epidermis. The 
term cutaneous neuroendocrine carcinoma may be 
the one that best describes the immunohistochemical 
and ultrastructural phenomena of these tumours, but 
the most widely used and ultrastructurally accepted 
name in the literature is MCC [1]. 
Merkel cell carcinoma (MCC) is typically 
presented as a painless, rapidly growing, cubist red or 
purple nodule of sun-exposed areas of the skin, such 
as the head and the neck, or the upper limbs. 
Aetiology is multifactorial, with immunosuppression, 
UV-induced skin damage and viral factors [2]. 
According to the NCCN, resection of a tumour 
in healthy tissue is the basic therapy. Patients at high 
risk may also undergo adjuvant radiotherapy. The role 
of chemotherapy is unclear. The incidence of Merkel 
cell carcinoma in the United States is estimated to be 
0.32/100.000 [3]. 
Merkel cell polyomavirus (MCPyV) was 
discovered in 2008 and still is the only human 
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polyomavirus that can be causally associated with 
human malignancy, i.e. Merkel cell carcinoma [4]. 
Merkel cell carcinoma is a highly aggressive 
tumour that often has a lethal end. Clonal colonisation 
with Merkel cell polyomavirus in the host genome may 
have a role in the carcinogenesis or the UV-induced 
carcinogenesis. Viral-encoded oncoproteins and UV-
induced mutations affect the related signalling 
pathway such as RB restriction of cell cycle 
progression or p53 inactivation. Although its relatively 
low incidence Merkel cell carcinoma has drawn much 
attention recently due to immunogenetics and 
immunomodulatory treatments [5]. 
MCC is characterised by the acronym (from 
English words) AEIOU.  
Most cases of MCC occur in a population at 
obvious high risk of developing this tumour. AEIOU 
features can be useful in identifying a suspected 
lesion [6] [7]. 
"A" is for asymptomatic. MCC is typically 
asymptomatic compared to an inflamed cyst, which it 
may sometimes resemble. 
"E" is for expanding rapidly; a node that 
increases in 1-2 months. 
"I" is for immunocompromised. 92% of 
patients with MCC are not immunocompromised, but 
those with long-standing T cell dysfunction (HIV, 
leukaemia, chronic immunosuppression) are at a 
much greater risk to develop MCC although they 
represent less than 10% of the cases.  
"O" is for patients older than 50 years. The 
risk of MCC increases with age due to the 
immunosenescence (the immune system is less 
capable of detecting immunogenic cancer). 
"U" is for the ultraviolet radiation-exposed fair 
skin. 
Ninety of the patients have 3 or more of the 
AEIOU features. But this is not specific since some 
lipomas or cysts can meet 2 or 3 criteria. 
Treatment is based on multidisciplinary 
management, although the optimal therapy is still 
controversial due to lack of data. Aggressive surgery, 
which is often associated with adjuvant radiotherapy, 
improves the locoregional recurrence and overall 
survival [8]. According to some authors, surgery and 
radiotherapy achieve excellent locoregional control. 
However, a certain percentage of patients develop a 
disseminated disease that is incurable. Chemotherapy 
has a great response in metastatic disease, but the 
response is short-lived, and the survival impact has 
not been established [9]. 
There are rare cases of metastatic disease. 
The disease usually metastasises in the local lymph 
nodes, but there are also cases of pleural metastases.
 
[10] Immunohistochemical analysis of a section 
stained with hematoxylin and eosin indicates tumour 
cells with infiltrative growth and hyperchromatic nuclei 
that have been positive for CK20, CD56, 
chromogranin and synaptophysin [11]. Survival at 5 
years is 51% for local disease and is low as 14% for 
distant disease, which underscores the aggressive 






The clinical examination is the first step in 
MCC diagnosis. The nonspecific and varied clinical 
features of this tumour pose certain diagnostic 
challenges even for an experienced dermatologist. 
Unlike basal cell carcinoma or melanoma, which may 
be clinically or dermatoscopically apparent, the 
“classic” MCC lesion does not exist [12].
 
A patient at 93 years of age comes for an 
examination by a dermatologist due to a rapidly 
growing erythematous nodule growth in the forehead 
area. A tumour was about 3 cm in size. It had no signs 
of basal-cell carcinoma, no arborising vascularisation, 
no pigmentations on dermatoscopy. The 
polymorphous vascular pattern has been observed. 
Clinically, an eventual Merkel cell carcinoma 
was considered for the patient, but other primary skin 
tumours had to be excluded, as well as the possibility 
that regarding the patient’s age, it may be a metastatic 
deposit [13]. 
A skin biopsy was performed, as well as H-E 
examination and immunohistochemical analyses 
(positive CD56, positivity of neuroendocrine markers 
synaptophysin, chromogranin) which were in favour of 
Merkel cell carcinoma of the skin. 
The biopsy specimen was formalin fixed and 
paraffin moulded. Besides the routine hematoxylin 
and eosin stained tissue sections, additional 
immunohistochemical analyses were performed on 
DAKO Autostainer link 48, an automatic 
immunohistochemical stainer, using monoclonal ready 
to use antibodies from Agilent Technologies. 
Histopathological analysis of the biopsy 
specimen detected a presence of neoplastic cells in 
the dermis, arranged in solid sheets with areas of 
"crush effect", composed of relatively uniform cells. 
The neoplastic cells had small basophilic nuclei and 
very scant cytoplasm consistent with the 
histopathological finding of small cell variant of MCC 
(Figure 1A). Numerous mitotic figures were evident. 
To confirm the neuroendocrine nature of the tumour 
cell, additional immunohistochemical analyses were 
performed. The immunohistochemical analysis 
indicated that tumour cells were positive for 
neuroendocrine markers chromogranin (Figure 1B) 
and synaptophysin (Figure 1C), whereas they were 
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negative for cytokeratins 5/6 (Figure 1D), cytokeratin 
7, CD45, TTF1, as well as for cytokeratin 20 (Figure 














Figure 1: A) Histological appearance of the tumor (hematoxilin and 
eosin, x200); B) Neoplastic cells show positivity for Chromogranin 
(x200); C) Neoplastic cells show positivity for Synaptophysin (x200); 
D) Neoplastic cells are negative for cytokeratins 5/6 (x200); E) 
Neoplastic cells are negative for cytokeratin 20 (x200); F) Ki-67 
proliferative index is >90% (x200) 
 
The performed CT examination indicated no 
presence of other tumour formations in the deep 
tissues of the head and the neck. The finding was 
normal. 
 
Figure 2: Patient before treatment 
 
After CT simulation in the patient, a plan for 
radiation of the skin efflorescence in the frontal area 
was made. The treatment used X-rays with an energy 
of 6MV and a total dose of 40 Gy during 10 fractions. 
The patient achieved a full-scale remission of the 
lesions. There was no tumour recurrence in the 
monitoring period of 3 months. 
  





Merkel cell carcinoma (MCC) usually has a 
clinical presentation in the form of a solitary, solid, 
well-defined nodule which is erythematous or purple, 
and mobile about the subcutaneous tissue. 
Staging classification of the disease is done 
according to the American Joint Committee on 
Cancer. 
Table 1: TNM Classification of MCC according to the American 
Joint Committee on Cancer 
Tumour Node Metastasis 
Tx, the tumour 
cannot be assessed 
Nx, lymph node involvement 
cannot be assessed 
Mx, metastasis cannot be 
assessed 
T0, no evidence of a 
primary tumour 
N0, no lymph node involvement M0, no metastasis 
This, primary tumour 
in situ 
-cN0, no clinical signs of lymph 
node involvement (on inspection, 
palpation, and radiograph) 
M1, distant metastasis 
T1, primary tumour 
≤ 2 cm 
-pN0, no lymph node 
involvement detected by a 
pathologist 
-M1a, metastasis to the 
skin, subcutaneous cellular 
tissue, or distant lymph 
nodes 
T2, primary 
tumour>2 cm and ≤ 
5 cm 
-pNx, no histology of lymph 
nodes 






 -M1c, metastasis to other 
visceral organs 
T4, a primary 
tumour affecting 
bone, muscle, 




 N2, in-transit metastasis
d
  
Abbreviations: MCC, Merkel cell carcinoma; a - Adapted by [1]; b - Micrometastases refer 
to clinically undetectable lymph nodes that are affected by the disease found in a sentinel 
lymph node or by elective dissection; c - Macrometastases refer to clinically evident and 
pathologically proven regional lymph nodes that are affected by the disease, using 
dissection or punch biopsy; d - In-transit metastases refer to metastases that are found 
between the primary tumor and the regional lymph nodes or distally of the primary tumor. 
 
After setting the diagnosis, our patient was 
treated with therapy which led to a complete 
withdrawal of a tumour. 
However, after 3 months the patient had 
repeated relapse of a tumour at the same site on the 
forehead and metastases in the retroauricular lymph 
nodes bilaterally. It shows that the radiotherapy as 
monotherapy has a great effect on the removal of the 
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tumour formation, but unfortunately, it has no impact 
on lesion recurrence. 
Table 2: Staging of MCC according to the American Joint 
Committee on Cancer 
Stage Tumour Lymph Nodes Metastasis 5-Year Survival, %
a
 
0 This N0 M0 100 
IA T1 pN0 M0 79 
IB T1 cN0 M0 60 
IIA T2/T3 pN0 M0 58 
IIB T2/T3 cN0 M0 49 
IIC T4 N0 M0 47 
IIIA Any T N1a M0 42 
IIIB Any T N1b/N2 M0 26 
IV Any T Any N M1 18 
Abbreviations: MCC, Merkel cell carcinoma. 
 
It is also compatible with the literature data. A 
study of 1.227 patients has proven that survival of 5 
years is greater in patients with performed resection of 
the tumour formation in healthy tissue, compared to 
the definite radiotherapy of the disease [11]. 
In conclusion, an increase of MCC incidence 
in recent years has drawn attention to this malignant 
disease that attacks older people. [14] This is 
especially relevant to the increase in patient's lifespan. 
Treatment of Merkel cell carcinoma on the head and 
the neck requires an early and adequate diagnosis so 
that proper treatment can start. AEIOU (acronym) rule 
can be of great help in raising suspicion to this 
tumour. It includes surgery, radiotherapy and/or 
combined chemotherapy. An adequate stage 
assessment of the cervical lymph node is of supreme 
importance prior starting the definitive plan for 
treatment of the disease [15]. 
Partial or complete regression of the tumour is 
also observed but is a rare phenomenon. Regression 
is accompanied by dense lymphocytic infiltrate 
predominantly from CD8 phenotype and apoptosis 
[16].
 
Definitive radiation monotherapy is an 
alternative to surgery, for patients who are poor 
surgical candidates, or those in whom surgery would 
result in significant functional compromise. The 
outcomes of radiation monotherapy may be inferior 
compared to complete surgical resection. Overall 
survival is decreased (37-39%, 5 years survival with 
radiation monotherapy) compared to complete 
surgical resection [17].
 
In many adult patients, as our 
case suggests (93 years old patient, 3 cm tumour 
size), radiotherapy could be considered as treatment 
opportunity, but is not preferable, since tumour 
relapse is seen soon afterwards. However, only if we 
can - not perform a wide surgical resection, because 
of functional disability and/or other co-morbidities, we 
could consider it as the first option, because Markel 
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